This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Solvay Pharmaceuticals, Gmbh, Vakzine Projekt Management Gmbh. Active years: 2007-2015.
Company Filing History:
Years Active: 2007-2015
Title: Bernd Eisele: Innovator in Biopharmaceuticals
Introduction
Bernd Eisele is a notable inventor based in Laatzen, Germany. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative treatments and vaccines. With a total of two patents to his name, Eisele's work focuses on enhancing therapeutic options for various medical conditions.
Latest Patents
Eisele's latest patents include a groundbreaking invention related to a combination of a bacterial cell and a biologically active agent. This invention aims to create a vaccine that induces an immune response in mammals. The first constituent of this combination is a bacterial cell containing a recombinant nucleic acid molecule that encodes a phagolysosomal escape peptide or polypeptide. The second constituent is a biologically active agent, which together can provide significant health benefits.
Another important patent by Eisele is a method for treating diseases that require the inhibition or reduction of the activity of pH value-regulating bicarbonate transporter proteins. This patent highlights the use of selective imidazoline receptor agonists, such as moxonidine and rilmenidine, in pharmaceutical preparations. These treatments target functional disorders and diseases in larger mammals or humans, including osteoporosis, gastric ulcers, and neuropsychiatric conditions like depression and Alzheimer's disease.
Career Highlights
Throughout his career, Bernd Eisele has worked with prominent companies in the pharmaceutical industry. He has been associated with Solvay Pharmaceuticals GmbH and Vakzine Projekt Management GmbH. His experience in these organizations has allowed him to contribute to the advancement of medical science and improve patient outcomes.
Collaborations
Eisele has collaborated with notable professionals in his field, including Heinz Rupp and Dieter Ziegler. These partnerships have facilitated the exchange of ideas and fostered innovation in biopharmaceutical research.
Conclusion
Bernd Eisele's contributions to the field of biopharmaceuticals through his patents and collaborations demonstrate his commitment to advancing medical science. His innovative approaches to vaccine development and treatment methods have the potential to significantly impact healthcare.